InvestorsHub Logo
Followers 31
Posts 2649
Boards Moderated 0
Alias Born 10/28/2013

Re: Doc logic post# 64176

Friday, 06/10/2016 9:25:20 PM

Friday, June 10, 2016 9:25:20 PM

Post# of 703842
Obviously the decision to provide a priority review should be based purely on potential efficacy / benefit. Obviously such should not be for sale or transfer even within the same organization to a different drug or even indication. Ridiculous!

I am not arguing with Sentiment, or ignoring the weight of what she is saying. This values the priority review. If those numbers are real, then a priority review is incredibly useful... so hopefully we have one going on.

But selling one! Ridiculous!
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News